-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Ulcerative colitis (UC) is a chronic disease with a high incidence and high recurrence rate.
At present, its etiology is not clear, and its pathogenesis is complicated.
It is usually considered to be caused by the combined effects of genetic factors, environmental factors, and immune factors.
To.
The main clinical manifestations of UC are abdominal pain, diarrhea, mucus, pus, blood and stool.
The lesions mostly involve the rectum and sigmoid colon.
More than 25% of UC patients have extraintestinal manifestations, such as peripheral arthritis and skin damage.
Biological agents are drugs that target the cells and proteins in the immune system and help control the symptoms of UC.
This article summarizes various biological agents that can be used to treat UC, including anti-tumor necrosis factor (TNF) drugs, integrin receptor antagonists, and interleukin inhibitors.
Anti-TNF drugs 1.
Adalimumab If the patient does not respond well to other immunosuppressants such as corticosteroids, azathioprine or 6-mercaptopurine, the doctor can prescribe Adalimumab.
In a clinical study, more than 17.
3% of UC subjects treated with adalimumab experienced remission after 52 weeks of treatment.
After receiving instructions from healthcare professionals, patients can inject adalimumab by themselves at home.
2.
Golimumab (golimumab) For UC patients who need continuous steroid therapy or have not found other effective drugs, doctors can prescribe golimumab.
A clinical trial showed that compared with patients who did not receive golimumab treatment, patients who received golimumab treatment for 6 weeks had more UC symptom relief, and endoscopy showed that the patient’s intestinal appearance was somewhat different.
improve.
Another trial showed that subjects received golimumab treatment for 30 and 54 weeks, and their symptoms maintained remission.
After receiving instructions from healthcare professionals, patients can inject golimumab by themselves at home.
3.
Infliximab (infliximab, IFX) If UC patients cannot benefit from other treatments, doctors can prescribe IFX.
IFX is the only anti-TNF drug that doctors can prescribe to children with UC (≥6 years of age).
In clinical studies, adult and pediatric subjects showed healing of the bowel wall under IFX treatment.
Integrin receptor antagonists Doctors can prescribe an integrin receptor antagonist called vedolizumab (VDZ) for moderate to severe adult UC patients, which is suitable for anti-TNF drugs intolerance or treatment failure Of patients, or for patients who are dependent on corticosteroids.
VDZ can begin to produce significant benefits after 6 weeks of treatment.
In clinical studies, compared with the control group, the treatment group achieved more remission after 52 weeks.
In addition, the researchers also found that the appearance of the intestines in the treatment group improved.
The interleukin inhibitor ustekinumab (UST) blocks the p40 subunits of interleukin (IL)-12 and IL-23, has low immunogenicity, and has been approved for psoriasis and psoriasis Treatment of arthritis and moderate to severe CD.
UST is suitable for adult patients and can lead to remission after 8 weeks.
In clinical studies, researchers found that UST can improve the appearance of patients' intestines.
Biological agents may cause side effects Biological agents can cause side effects.
Many of the above biological preparations need to be injected, and patients may experience symptoms such as redness, itching, bruising, pain, and swelling at the injection site.
Other side effects of biological agents include: headache, fever, chills, urticaria, rash, etc.
If the side effects are uncomfortable or suggest an allergic reaction, the patient should seek medical attention immediately.
Related reading Drug Evaluation: Which drugs are safer in the treatment of inflammatory bowel disease? References: [1] Zhang Guoxing, Shi Rong.
Progress in the treatment of ulcerative colitis[J].
Modern Journal of Integrated Traditional Chinese and Western Medicine, 2019,28(25):2842-2847.
[2] Caporuscio J.
What to know about biologics for ulcerative colitis.
MedicalNewsToday.
2021 Feb 25.
[3] Wu Quanfeng, Zhao Libo, Wang Xiaoling, et al.
Research progress in the treatment of inflammatory bowel disease[J].
China Pharmacist, 2020,23(10):2011-2019.
Contribution Email : Tougao@medlive.
cn
At present, its etiology is not clear, and its pathogenesis is complicated.
It is usually considered to be caused by the combined effects of genetic factors, environmental factors, and immune factors.
To.
The main clinical manifestations of UC are abdominal pain, diarrhea, mucus, pus, blood and stool.
The lesions mostly involve the rectum and sigmoid colon.
More than 25% of UC patients have extraintestinal manifestations, such as peripheral arthritis and skin damage.
Biological agents are drugs that target the cells and proteins in the immune system and help control the symptoms of UC.
This article summarizes various biological agents that can be used to treat UC, including anti-tumor necrosis factor (TNF) drugs, integrin receptor antagonists, and interleukin inhibitors.
Anti-TNF drugs 1.
Adalimumab If the patient does not respond well to other immunosuppressants such as corticosteroids, azathioprine or 6-mercaptopurine, the doctor can prescribe Adalimumab.
In a clinical study, more than 17.
3% of UC subjects treated with adalimumab experienced remission after 52 weeks of treatment.
After receiving instructions from healthcare professionals, patients can inject adalimumab by themselves at home.
2.
Golimumab (golimumab) For UC patients who need continuous steroid therapy or have not found other effective drugs, doctors can prescribe golimumab.
A clinical trial showed that compared with patients who did not receive golimumab treatment, patients who received golimumab treatment for 6 weeks had more UC symptom relief, and endoscopy showed that the patient’s intestinal appearance was somewhat different.
improve.
Another trial showed that subjects received golimumab treatment for 30 and 54 weeks, and their symptoms maintained remission.
After receiving instructions from healthcare professionals, patients can inject golimumab by themselves at home.
3.
Infliximab (infliximab, IFX) If UC patients cannot benefit from other treatments, doctors can prescribe IFX.
IFX is the only anti-TNF drug that doctors can prescribe to children with UC (≥6 years of age).
In clinical studies, adult and pediatric subjects showed healing of the bowel wall under IFX treatment.
Integrin receptor antagonists Doctors can prescribe an integrin receptor antagonist called vedolizumab (VDZ) for moderate to severe adult UC patients, which is suitable for anti-TNF drugs intolerance or treatment failure Of patients, or for patients who are dependent on corticosteroids.
VDZ can begin to produce significant benefits after 6 weeks of treatment.
In clinical studies, compared with the control group, the treatment group achieved more remission after 52 weeks.
In addition, the researchers also found that the appearance of the intestines in the treatment group improved.
The interleukin inhibitor ustekinumab (UST) blocks the p40 subunits of interleukin (IL)-12 and IL-23, has low immunogenicity, and has been approved for psoriasis and psoriasis Treatment of arthritis and moderate to severe CD.
UST is suitable for adult patients and can lead to remission after 8 weeks.
In clinical studies, researchers found that UST can improve the appearance of patients' intestines.
Biological agents may cause side effects Biological agents can cause side effects.
Many of the above biological preparations need to be injected, and patients may experience symptoms such as redness, itching, bruising, pain, and swelling at the injection site.
Other side effects of biological agents include: headache, fever, chills, urticaria, rash, etc.
If the side effects are uncomfortable or suggest an allergic reaction, the patient should seek medical attention immediately.
Related reading Drug Evaluation: Which drugs are safer in the treatment of inflammatory bowel disease? References: [1] Zhang Guoxing, Shi Rong.
Progress in the treatment of ulcerative colitis[J].
Modern Journal of Integrated Traditional Chinese and Western Medicine, 2019,28(25):2842-2847.
[2] Caporuscio J.
What to know about biologics for ulcerative colitis.
MedicalNewsToday.
2021 Feb 25.
[3] Wu Quanfeng, Zhao Libo, Wang Xiaoling, et al.
Research progress in the treatment of inflammatory bowel disease[J].
China Pharmacist, 2020,23(10):2011-2019.
Contribution Email : Tougao@medlive.
cn
